Shenzhen - Delayed Quote CNY

Acrobiosystems Co.,Ltd. (301080.SZ)

50.11
-0.46
(-0.91%)
At close: 3:04:31 PM GMT+8
Loading Chart for 301080.SZ
  • Previous Close 50.57
  • Open 48.50
  • Bid 50.09 x --
  • Ask 50.11 x --
  • Day's Range 49.89 - 50.87
  • 52 Week Range 31.30 - 59.94
  • Volume 1,318,250
  • Avg. Volume 1,793,736
  • Market Cap (intraday) 6.013B
  • Beta (5Y Monthly) 0.79
  • PE Ratio (TTM) 45.14
  • EPS (TTM) 1.11
  • Earnings Date --
  • Forward Dividend & Yield 1.20 (2.54%)
  • Ex-Dividend Date Jan 24, 2025
  • 1y Target Est 58.92

Acrobiosystems Co.,Ltd. engages in the development and manufacture of recombinant proteins, antibodies, and other biological reagents for pharmaceutical and biotechnology companies, and scientific research institutions. The company has a collaboration with Diagnostic Biochips Inc for neurological drug discovery and commercialization. The company was founded in 2010 and is based in Beijing, China.

www.acrobiosystems.cn

869

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 301080.SZ

View More

Performance Overview: 301080.SZ

Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

301080.SZ
14.21%
SSE Composite Index (000001.SS)
1.56%

1-Year Return

301080.SZ
23.42%
SSE Composite Index (000001.SS)
8.21%

3-Year Return

301080.SZ
42.99%
SSE Composite Index (000001.SS)
10.36%

5-Year Return

301080.SZ
62.04%
SSE Composite Index (000001.SS)
18.59%

Compare To: 301080.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 301080.SZ

View More

Valuation Measures

Annual
As of 5/13/2025
  • Market Cap

    6.07B

  • Enterprise Value

    4.35B

  • Trailing P/E

    45.39

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    8.86

  • Price/Book (mrq)

    2.32

  • Enterprise Value/Revenue

    6.35

  • Enterprise Value/EBITDA

    30.69

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    19.20%

  • Return on Assets (ttm)

    1.30%

  • Return on Equity (ttm)

    4.62%

  • Revenue (ttm)

    645.02M

  • Net Income Avi to Common (ttm)

    123.83M

  • Diluted EPS (ttm)

    1.11

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.89B

  • Total Debt/Equity (mrq)

    5.39%

  • Levered Free Cash Flow (ttm)

    -156.74M

Research Analysis: 301080.SZ

View More

Company Insights: 301080.SZ

Research Reports: 301080.SZ

View More

People Also Watch